Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.

@article{Meiners2012ResponsivenessOD,
  title={Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj{\"o}gren's syndrome treated with rituximab.},
  author={Petra Mari{\"e}lle Meiners and Suzanne Arends and Elisabeth Cath{\'e}rine Brouwer and Frederik K. L. Spijkervet and A Vissink and Hendrika Bootsma},
  journal={Annals of the rheumatic diseases},
  year={2012},
  volume={71 8},
  pages={1297-302}
}
OBJECTIVE To evaluate the responsiveness of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) in patients with primary Sjögren's syndrome (pSS) treated with rituximab. METHODS Twenty-eight patients with pSS treated with rituximab (1000 mg) infusions on days 1 and 15 were included in the study. Data were collected prospectively at baseline and 16, 24, 36, 48 and 60 weeks after treatment. Internal responsiveness was… CONTINUE READING